Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 61 articles:
HTML format



Single Articles


    March 2023
  1. BEISER ME, Shaw LC, Shores SK, Carson JM, et al
    Hepatitis C virus reinfection in a real-world cohort of homeless-experienced individuals in Boston.
    Clin Infect Dis. 2023 Mar 4:ciad127. doi: 10.1093.
    PubMed     Abstract available


    January 2023
  2. HERNANDEZ-TAMAYO C, Qato DM, Jewell MP, Gounder P, et al
    COVID-19 Pandemic Associated Declines and Subsequent Increases in Hepatitis C Virus Treatment Prescriptions in Los Angeles County.
    Clin Infect Dis. 2023 Jan 31:ciad050. doi: 10.1093.
    PubMed    


  3. SOWAH LA, Smeaton L, Brates I, Bhattacharya D, et al
    Perspectives on Adherence from the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach with 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
    Clin Infect Dis. 2023 Jan 24:ciad034. doi: 10.1093.
    PubMed     Abstract available


  4. AHRENS K, Sharbaugh M, Jarlenski MP, Tang L, et al
    Prevalence of testing for HIV, HBV, and HCV among Medicaid enrollees treated with medications for opioid use disorder in 11 states, 2016-2019.
    Clin Infect Dis. 2023 Jan 3:ciac981. doi: 10.1093.
    PubMed     Abstract available


    December 2022
  5. POLITI J, Regidor E, Donat M, Pulido J, et al
    Free access to direct-acting antivirals in Spain: more favorable impact on hepatitis C mortality among highly educated people.
    Clin Infect Dis. 2022 Dec 6:ciac928. doi: 10.1093.
    PubMed     Abstract available


    November 2022
  6. THOMAS DL, Kiser JJ, Baum MM
    Long-Acting Treatments for Hepatitis B.
    Clin Infect Dis. 2022;75.
    PubMed     Abstract available


  7. OLAGUNJU A, Mathad J, Eke A, Delaney-Moretlwe S, et al
    Considerations for the Use of Long-Acting and Extended-Release Agents During Pregnancy and Lactation.
    Clin Infect Dis. 2022;75.
    PubMed     Abstract available


  8. THOMAS DL, Owen A, Kiser JJ
    Prospects for Long-Acting Treatments for Hepatitis C.
    Clin Infect Dis. 2022;75.
    PubMed     Abstract available


    October 2022
  9. HOFMANN E, Surial B, Boillat-Blanco N, Gunthard HF, et al
    HBV REPLICATION DURING TENOFOVIR THERAPY IS FREQUENT IN HIV/HBV-COINFECTION.
    Clin Infect Dis. 2022 Oct 15. pii: 6761485. doi: 10.1093.
    PubMed     Abstract available


  10. JACOB JS, Shaikh A, Goli K, Rich NE, et al
    Improved Survival after Liver Transplantation for Patients with HIV and HIV/HCV Coinfection in the INSTI and DAA eras.
    Clin Infect Dis. 2022 Oct 12. pii: 6758523. doi: 10.1093.
    PubMed     Abstract available


    September 2022
  11. BALIASHVILI D, Blumberg HM, Benkeser D, Kempker RR, et al
    Association of treated and untreated chronic hepatitis C with the incidence of active tuberculosis disease: a population-based cohort study.
    Clin Infect Dis. 2022 Sep 22. pii: 6711147. doi: 10.1093.
    PubMed     Abstract available


  12. CHEW KW, Wu K, Tassiopoulos K, Palella FJ, et al
    Liver inflammation is common and linked to metabolic derangements in persons with treated HIV.
    Clin Infect Dis. 2022 Sep 1. pii: 6682837. doi: 10.1093.
    PubMed     Abstract available


    August 2022
  13. MONIN MB, Ingiliz P, Lutz T, Scholten S, et al
    Low spontaneous clearance rates of recently acquired hepatitis C virus in HIV-positive MSM (The PROBE-C Study).
    Clin Infect Dis. 2022 Aug 25. pii: 6675078. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  14. HUDSON AG, Bonacci RA, Moorman AC, Penley M, et al
    Hepatitis C virus infection preceding an outbreak of HIV among persons who inject drugs- Kanawha County, West Virginia, 2019-2021.
    Clin Infect Dis. 2022 Jul 29. pii: 6651445. doi: 10.1093.
    PubMed     Abstract available


  15. HSU HY, Chen HL, Chiang CL, Lai MW, et al
    Characterization of Hepatitis B Virus in Tenofovir-Treated and Untreated Chronically Infected Mothers and Their Immunoprophylaxis Failure Infants.
    Clin Infect Dis. 2022 Jul 5. pii: 6629403. doi: 10.1093.
    PubMed     Abstract available


  16. MARATHE G, Moodie EE, Brouillette MJ, Delaunay CL, et al
    Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population in Canada.
    Clin Infect Dis. 2022 Jul 5. pii: 6629407. doi: 10.1093.
    PubMed     Abstract available


    May 2022
  17. MAK LY, Cheung KS, Hui RW, Wong DK, et al
    Enhanced liver fibrosis score stratifies hepatocellular carcinoma risk in patients with hepatitis B surface antigen seroclearance.
    Clin Infect Dis. 2022 May 20. pii: 6589789. doi: 10.1093.
    PubMed     Abstract available


  18. CHOW N, Wong D, Lai CL, Mak LY, et al
    Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion.
    Clin Infect Dis. 2022 May 20. pii: 6589784. doi: 10.1093.
    PubMed     Abstract available


  19. WONG RJ, Kaufman HW, Niles JK, Kapoor H, et al
    Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination.
    Clin Infect Dis. 2022 May 20. pii: 6589786. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  20. JHAVERI R
    Elimination Means Everyone: Targeting Hepatitis C in Infants and Pregnant Patients.
    Clin Infect Dis. 2022 Apr 27. pii: 6574818. doi: 10.1093.
    PubMed    


  21. JOHANNESSON JM, Fridriksdottir RH, Love TJ, Runarsdottir V, et al
    HIGH RATE OF HCV REINFECTION AMONG RECENTLY INJECTING DRUG USERS: RESULTS FROM THE TRAP HEP C PROGRAM - A PROSPECTIVE NATIONWIDE, POPULATION-BASED STUDY.
    Clin Infect Dis. 2022 Apr 19. pii: 6570478. doi: 10.1093.
    PubMed     Abstract available


  22. GROVES J, Dodd RY, Foster GA, Stramer SL, et al
    Genotype Distribution and Demographic Characteristics of Hepatitis C Virus NAT Yield Cases among US Blood Donors.
    Clin Infect Dis. 2022 Apr 11. pii: 6566326. doi: 10.1093.
    PubMed     Abstract available


  23. KUSEJKO K, Salazar-Vizcaya L, Shah C, Stockle M, et al
    Sustained effect on hepatitis C elimination among men who have sex with men in the Swiss HIV Cohort Study: A systematic re-screening for hepatitis C RNA two years following a nation-wide elimination program.
    Clin Infect Dis. 2022 Apr 11. pii: 6566325. doi: 10.1093.
    PubMed     Abstract available


  24. ADES AE, Gordon F, Scott K, Collins IJ, et al
    Overall vertical transmission of HCV, transmission net of clearance, and timing of transmission.
    Clin Infect Dis. 2022 Apr 11. pii: 6566315. doi: 10.1093.
    PubMed     Abstract available


  25. ADES AE, Gordon F, Scott K, Collins IJ, et al
    Spontaneous Clearance Of Vertically Acquired Hepatitis C Infection: Implications For Testing And Treatment.
    Clin Infect Dis. 2022 Apr 9. pii: 6565752. doi: 10.1093.
    PubMed     Abstract available


  26. CARSON JM, Dore GJ, Lloyd AR, Grebely J, et al
    Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study.
    Clin Infect Dis. 2022 Apr 1. pii: 6562011. doi: 10.1093.
    PubMed     Abstract available


    March 2022
  27. AMIN J, Vaccher S, Templeton DJ, Bavinton B B, et al
    Low prior exposure and incidence of hepatitis C in HIV negative gay and bisexual men taking PrEP: findings from the EPIC-NSW prospective implementation study.
    Clin Infect Dis. 2022 Mar 30. pii: 6555792. doi: 10.1093.
    PubMed     Abstract available


  28. LEE TH, Hunt CM, Maier MM, Lowy E, et al
    Hepatitis B Virus-Related Care Quality In Patients With Hepatitis B/Hiv Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study.
    Clin Infect Dis. 2022 Mar 29. pii: 6555659. doi: 10.1093.
    PubMed     Abstract available


  29. MOUTCHIA J, Njouom R, Rumpler E, Besombes C, et al
    Maternal Age at First Childbirth and Geographical Variation in Hepatitis B Virus Prevalence in Cameroon: Important Role of Mother-to-Child Transmission.
    Clin Infect Dis. 2022;74:836-845.
    PubMed     Abstract available


  30. HOENIGL M, Abramovitz D, Flores Ortega RE, Martin NK, et al
    Sustained impact of the COVID-2019 pandemic on HCV treatment initiations in the United States.
    Clin Infect Dis. 2022 Mar 2. pii: 6540915. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  31. TRICKEY A, Croxford S, Emanuel E, Ijaz S, et al
    The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in England, Wales, and Northern Ireland.
    Clin Infect Dis. 2022 Feb 20. pii: 6532589. doi: 10.1093.
    PubMed     Abstract available


  32. TESHALE EH, Roberts H, Gupta N, Jiles R, et al
    Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014-2020.
    Clin Infect Dis. 2022 Feb 16. pii: 6529537. doi: 10.1093.
    PubMed     Abstract available


  33. GORDON SC, Teshale EH, Spradling PR, Moorman AC, et al
    Lower rates of emergency visits and hospitalizations among chronic hepatitis C patients with sustained virological response to interferon-free direct-acting antiviral therapy (2014-2018).
    Clin Infect Dis. 2022 Feb 11. pii: 6526938. doi: 10.1093.
    PubMed     Abstract available


    December 2021
  34. HUANG YC, Sun HY, Sheng WH, Hsieh SM, et al
    Evolution of hepatitis B virus (HBV) serologic markers among antiretroviral-naive, young people living with HIV who had undergone neonatal HBV vaccination and initiated antiretroviral therapy.
    Clin Infect Dis. 2021 Dec 10. pii: 6459150. doi: 10.1093/cid/ciab1020.
    PubMed     Abstract available


  35. LIU CJ, Sheen IS, Chen CY, Chuang WL, et al
    Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up 108 Weeks Posttreatment.
    Clin Infect Dis. 2021 Dec 2. pii: 6448442. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  36. LIU S, Deng R, Zhou B, Sun J, et al
    Is the World Health Organization Hepatitis B Virus (HBV) DNA Standard Appropriate for Standardizing Serum HBV RNA Assays?
    Clin Infect Dis. 2021;73:e2821-e2823.
    PubMed    


  37. WORETA TA, Chalasani N
    Fatty Liver Disease in Human Immunodeficiency Virus-Hepatitis B Virus Coinfection: A Cause for Concern.
    Clin Infect Dis. 2021;73:e3286-e3287.
    PubMed    


  38. LEE JH, Lee YB, Cho EJ, Yu SJ, et al
    Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study.
    Clin Infect Dis. 2021;73:e3308-e3316.
    PubMed     Abstract available


    October 2021
  39. SRIDHAR S, Yip CC, Lo KH, Wu S, et al
    Hepatitis E virus species C infection in humans, Hong Kong.
    Clin Infect Dis. 2021 Oct 27. pii: 6412704. doi: 10.1093.
    PubMed     Abstract available


  40. WELD ED, Astemborski J, Kirk GD, Sulkowski MS, et al
    Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments.
    Clin Infect Dis. 2021 Oct 26. pii: 6410743. doi: 10.1093.
    PubMed     Abstract available


  41. KHALILI M, King WC, Kleiner DE, Chung RT, et al
    Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection.
    Clin Infect Dis. 2021 Oct 25. pii: 6410628. doi: 10.1093.
    PubMed     Abstract available


  42. HARNEY BL, Sacks-Davis R, van Santen DK, Traeger M, et al
    The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009-2019.
    Clin Infect Dis. 2021 Oct 25. pii: 6410633. doi: 10.1093.
    PubMed     Abstract available


    September 2021
  43. BAROCAS JA, Savinkina A, Lodi S, Epstein RL, et al
    Projected long-term impact of the COVID-19 pandemic on hepatitis C outcomes in the United States: a modelling study.
    Clin Infect Dis. 2021 Sep 9. pii: 6367757. doi: 10.1093.
    PubMed     Abstract available


  44. GAO Y, Kong F, Song X, Shang J, et al
    Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial.
    Clin Infect Dis. 2021 Sep 6. pii: 6364928. doi: 10.1093.
    PubMed     Abstract available


    August 2021
  45. TULLY DC, Hahn JA, Bean DJ, Evans JL, et al
    Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships.
    Clin Infect Dis. 2021 Aug 27. pii: 6358610. doi: 10.1093.
    PubMed     Abstract available


  46. LIU L, Wang L, Zhang H, Ou W, et al
    Changing Epidemiology of Hepatitis B Virus and Hepatitis C Virus Coinfection in a Human Immunodeficiency Virus-Positive Population in China: Results From the Third and Fourth Nationwide Molecular Epidemiologic Surveys.
    Clin Infect Dis. 2021;73:642-649.
    PubMed     Abstract available


    July 2021
  47. GORMLEY MA, Akiyama MJ, Rennert L, Howard KA, et al
    Changes in health-related quality of life for HCV-infected people who inject drugs on opioid agonist treatment following sustained virologic response.
    Clin Infect Dis. 2021 Jul 31. pii: 6332893. doi: 10.1093.
    PubMed     Abstract available


  48. IJAZ S, Derrick J, Shute J, Ireland G, et al
    Mother To Infant Transmission Of Hepatitis B Virus In The Face Of Neonatal Immunisation Is Not Necessarily Primary Vaccine Failure.
    Clin Infect Dis. 2021 Jul 12. pii: 6319332. doi: 10.1093.
    PubMed     Abstract available


  49. DEZANET LNC, Kassime R, Miailhes P, Lascoux-Combe C, et al
    Effect of viral replication and liver fibrosis on all-cause mortality in HIV/HBV coinfected individuals: a retrospective analysis of a 15-year longitudinal cohort.
    Clin Infect Dis. 2021 Jul 1. pii: 6312684. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  50. BARTLETT SR, Wong S, Yu A, Pearce M, et al
    The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study.
    Clin Infect Dis. 2021 Jun 14. pii: 6298569. doi: 10.1093.
    PubMed     Abstract available


  51. VALERIO H, Alavi M, Law M, McManus H, et al
    Opportunities to enhance linkage to hepatitis C care among hospitalised people with recent drug dependence in New South Wales, Australia: A population-based linkage study.
    Clin Infect Dis. 2021 Jun 9. pii: 6295650. doi: 10.1093.
    PubMed     Abstract available


  52. ONOFRIO FQ, Cooper C, Borgia SM, Vachon ML, et al
    Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
    Clin Infect Dis. 2021;72:e799-e805.
    PubMed     Abstract available


    May 2021
  53. BOEKE CE, Hiebert L, Waked I, Tsertsvadze T, et al
    Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes from National Treatment Programs in Three Low- and Middle-Income Countries.
    Clin Infect Dis. 2021 May 20. pii: 6279051. doi: 10.1093.
    PubMed     Abstract available


  54. TOY M, Hutton D, Harris AM, Nelson N, et al
    Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
    Clin Infect Dis. 2021 May 6. pii: 6270943. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  55. HEO M, Pericot-Valverde I, Rennert L, Akiyama MJ, et al
    Hepatitis C virus DAA treatment adherence patterns and SVR among people who inject drugs treated in opioid agonist therapy programs.
    Clin Infect Dis. 2021 Apr 20. pii: 6238636. doi: 10.1093.
    PubMed     Abstract available


  56. MERAT S, Sharifi AH, Poustchi H, Hajiani E, et al
    Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial.
    Clin Infect Dis. 2021 Apr 15. pii: 6226813. doi: 10.1093/cid/ciaa1768.
    PubMed    


  57. LEE SK, Sung PS, Park SS, Min CK, et al
    Reactivation of resolved hepatitis B after daratumumab for multiple myeloma.
    Clin Infect Dis. 2021 Apr 13. pii: 6224403. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  58. ZHANG H, Wang F, Zhu X, Chen Y, et al
    Antiviral Activity and Pharmacokinetics of the HBV Capsid Assembly Modulator GLS4 in Patients with Chronic HBV Infection.
    Clin Infect Dis. 2020 Jul 10. pii: 5869864. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  59. CHANCHAROENTHANA W, Leelahavanichkul A
    Kidney Transplantation from HBsAg+ Living Donors to HBsAg- Recipients: Benefits and Risks.
    Clin Infect Dis. 2020 Jun 3. pii: 5850914. doi: 10.1093.
    PubMed    


    February 2020
  60. WANG XD, Liu JP, Song TR, Huang ZL, et al
    Kidney Transplantation from HBsAg+ Living Donors to HBsAg- Recipients: Clinical Outcomes at a High-volume Center in China.
    Clin Infect Dis. 2020 Feb 26. pii: 5758069. doi: 10.1093.
    PubMed     Abstract available


    December 2019
  61. BOGLIONE L, Lipani F, Lucchini AM, Salvador E, et al
    Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue.
    Clin Infect Dis. 2019 Dec 17. pii: 5679635. doi: 10.1093/cid/ciz1199.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: